Clinical Trial Update: A Phase II Study of Belinostat in Combination With Bortezomib in Patients With Relapsed, Refractory Multiple Myeloma [Phase 2]

View source ↗

Summary

A Phase II trial evaluating belinostat in combination with bortezomib for relapsed and refractory multiple myeloma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• BELEODAQ (BELINOSTAT)
• Velcade (bortezomib)

Snippet

Sponsor: Valerio Therapeutics | Conditions: Multiple Myeloma | Phase 2 | Status: TERMINATED